| First Author | Kugimiya F | Year | 2007 |
| Journal | PLoS One | Volume | 2 |
| Issue | 9 | Pages | e837 |
| PubMed ID | 17786208 | Mgi Jnum | J:129364 |
| Mgi Id | MGI:3769169 | Doi | 10.1371/journal.pone.0000837 |
| Citation | Kugimiya F, et al. (2007) GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS One 2(9):e837 |
| abstractText | Despite accumulated knowledge of various signalings regulating bone formation, the molecular network has not been clarified sufficiently to lead to clinical application. Here we show that heterozygous glycogen synthase kinase-3beta (GSK-3beta)-deficient mice displayed an increased bone formation due to an enhanced transcriptional activity of Runx2 by suppressing the inhibitory phosphorylation at a specific site. The cleidocranial dysplasia in heterozygous Runx2-deficient mice was significantly rescued by the genetic insufficiency of GSK-3beta or the oral administration of lithium chloride, a selective inhibitor of GSK-3beta. These results establish GSK-3beta as a key attenuator of Runx2 activity in bone formation and as a potential molecular target for clinical treatment of bone catabolic disorders like cleidocranial dysplasia. |
